Publications in collaboration with researchers from Eli Lilly and Company (11)

2023

  1. Genetic analysis of blood molecular phenotypes reveals common properties in the regulatory networks affecting complex traits

    Nature Communications, Vol. 14, Núm. 1

  2. Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials

    The Lancet Diabetes and Endocrinology, Vol. 11, Núm. 1, pp. 33-41

2022

  1. Response to: 'Use of tanezumab for patients with hip and knee osteoarthritis with reference to a randomised clinical trial by Berenbaum and colleagues' by Riddle and Perera

    Annals of the Rheumatic Diseases

2021

  1. Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?

    European Journal of Pain (United Kingdom), Vol. 25, Núm. 7, pp. 1525-1539

  2. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

    The Lancet, Vol. 398, Núm. 10313, pp. 1811-1824

2020

  1. A reference map of potential determinants for the human serum metabolome

    Nature, Vol. 588, Núm. 7836, pp. 135-140

  2. Subcutaneous tanezumab for osteoarthritis of the hip or knee: Efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period

    Annals of the Rheumatic Diseases, Vol. 79, Núm. 6, pp. 800-810

2019

  1. Genetic studies of abdominal MRI data identify genes regulating hepcidin as major determinants of liver iron concentration

    Journal of Hepatology, Vol. 71, Núm. 3, pp. 594-602

2015

  1. Prevalence of fractures in women with rheumatoid arthritis and/or systemic lupus erythematosus on chronic glucocorticoid therapy Epidemiology of musculoskeletal disorders

    BMC Musculoskeletal Disorders, Vol. 16, Núm. 1

2007

  1. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial

    Lancet Oncology, Vol. 8, Núm. 3, pp. 219-225

2005

  1. Docetaxel/gemcitabine administered every other week as first-line treatment for metastatic breast cancer: Final results of a phase II trial

    Clinical Breast Cancer, Vol. 6, Núm. 5, pp. 433-438